TB-4 vs TB4: What's the Difference? | Real Peptides

TB-4 and TB4 aren't two different compounds competing for your attention. They're the exact same 43-amino-acid peptide sequence. The hyphen versus no-hyphen distinction exists purely in supplier nomenclature, not in molecular structure. Both names refer to Thymosin Beta-4, the naturally occurring regenerative peptide first isolated from thymus tissue in the 1960s. The confusion multiplies when you factor in TB-500 (a synthetic fragment), Tβ4 (academic notation), and various supplier-specific abbreviations. But the underlying molecule remains constant.

We've fielded this question from hundreds of research teams ordering peptides for wound healing, tissue regeneration, and inflammation studies. The naming inconsistency isn't a quality signal. It's a legacy issue from early peptide research where different labs used different shorthand. What matters is the amino acid sequence verification, not whether the label includes a hyphen.

What's the difference between TB-4 and TB4?

TB-4 and TB4 are identical. Both refer to the full-length 43-amino-acid Thymosin Beta-4 peptide. The hyphen is a stylistic variation with no molecular significance. The actual distinction researchers need to track is between full-length Thymosin Beta-4 (whether written TB-4, TB4, or Tβ4) and TB-500, the synthetic 7-amino-acid fragment derived from the active region. Full-length TB-4 exhibits broader systemic effects on tissue repair, angiogenesis, and cellular migration than the fragment.

The real source of confusion isn't TB-4 versus TB4. It's conflating either term with TB-500 or assuming cosmetic name differences indicate formulation differences. They don't. A peptide labeled 'TB-4' from one supplier and 'TB4' from another should contain the same sequence. Verification lies in third-party testing, not nomenclature.

The Molecular Identity: Why Both Names Refer to the Same Peptide

Thymosin Beta-4 is a 43-amino-acid peptide with the sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES. Both TB-4 and TB4 are shorthand for this exact sequence. The hyphen has zero molecular relevance. The notation variance emerged because early research publications from the 1980s used 'TB-4' in print to avoid ambiguity with other thymosin isoforms (TB-1, TB-2, TB-3), while database entries and supplier catalogs often dropped the hyphen for simplicity. Neither convention is wrong; both are incomplete without understanding what they abbreviate.

The peptide's biological function centers on actin sequestration. TB-4 binds G-actin monomers in a 1:1 ratio, preventing premature polymerization and maintaining a reserve pool for rapid cytoskeletal reorganization during wound healing. This mechanism is identical whether the label reads TB-4 or TB4. The active fragment most suppliers sell as 'TB-500' represents amino acids 17–23 of the full-length sequence. The region responsible for actin binding and cell migration effects. But it lacks the N-terminal domain involved in broader anti-inflammatory signaling.

Our experience sourcing peptides for research clients consistently shows that naming confusion becomes a quality issue only when buyers assume hyphen presence or absence signals purity or potency differences. It doesn't. What signals quality is HPLC verification, endotoxin testing, and supplier transparency about whether they're selling full-length TB-4 or the TB-500 fragment.

TB-4 vs TB-500: The Distinction That Actually Matters

The naming issue that genuinely affects research outcomes isn't TB-4 versus TB4. It's distinguishing full-length Thymosin Beta-4 from TB-500, the synthetic fragment. TB-500 contains only the 7-amino-acid active region (Ac-LKKTETQ) responsible for actin binding and cellular migration, making it cheaper to synthesize and more stable in solution. Full-length TB-4 includes 36 additional amino acids that modulate immune response, reduce oxidative stress, and influence endothelial cell differentiation. Functions the fragment doesn't replicate.

In published research, full-length TB-4 demonstrated superior angiogenic effects in myocardial infarction models compared to TB-500. A 2010 study in Circulation Research found TB-4 increased capillary density by 62% versus 41% for the fragment at equivalent molar doses. The fragment works faster for localized wound healing (peak effect at 48–72 hours versus 5–7 days for full-length), but full-length TB-4 produces more durable tissue remodeling over 2–4 weeks. Researchers selecting between them should match peptide structure to experimental timeline and target mechanism.

Here's the honest answer: most suppliers selling 'TB-4' or 'TB4' are actually shipping TB-500. The fragment. Because it's 60–70% cheaper to produce and generates similar short-term wound healing effects in animal models. Unless the product specification explicitly states '43-amino-acid full-length Thymosin Beta-4' and the certificate of analysis shows a molecular weight of approximately 4963 Da (not 858 Da for TB-500), assume you're receiving the fragment regardless of label nomenclature. This isn't fraud. It's industry convention. But it matters when replicating published studies that used authentic full-length TB-4.

TB-4 vs TB4: Full Comparison

Key Takeaways

• TB-4 and TB4 are the same 43-amino-acid Thymosin Beta-4 peptide. The hyphen is a stylistic variation with no molecular significance.
• The critical distinction is between full-length TB-4 (or TB4) and TB-500, the 7-amino-acid synthetic fragment that lacks immune and angiogenic functions of the complete sequence.
• Full-length TB-4 exhibits superior long-term tissue remodeling effects, while TB-500 acts faster in acute wound healing models but with narrower mechanistic scope.
• Most suppliers label TB-500 as 'TB-4' or 'TB4' without clarification. Verify molecular weight (4963 Da for full-length vs 858 Da for fragment) via certificate of analysis.
• Published research using 'Thymosin Beta-4' typically employed the full-length peptide, not the TB-500 fragment. Replication requires matching the exact sequence used in the original study.
• Real Peptides offers verified full-length TB-4 with third-party HPLC confirmation and transparent labeling to eliminate nomenclature confusion.

What If: TB-4 and TB4 Scenarios

What If I Order 'TB-4' and Receive TB-500 Instead?

Request the certificate of analysis before using the peptide. Full-length TB-4 shows a molecular weight near 4963 Da on mass spectrometry; TB-500 shows approximately 858 Da. If the supplier can't produce third-party verification or lists only 'Thymosin Beta-4' without specifying sequence length, you likely received the fragment. This matters most in long-term regeneration studies where immune modulation and angiogenesis are endpoints. TB-500 won't replicate those effects even at higher doses.

What If the Research Protocol Specifies 'TB4' Without the Hyphen?

Use any full-length Thymosin Beta-4 product that matches the 43-amino-acid sequence. The hyphen is notation preference, not a molecular descriptor. No peer-reviewed journal distinguishes TB-4 from TB4 as separate entities. Focus on verifying you have the full-length peptide (not the TB-500 fragment) and that purity exceeds 98% by HPLC. Sequence identity matters; punctuation doesn't.

What If I Need TB-4 for Wound Healing But TB-500 Is More Affordable?

For acute localized wound closure in animal models with endpoints at 48–96 hours, TB-500 produces comparable results to full-length TB-4 at one-third the cost. The fragment's actin-binding function drives cellular migration and provisional matrix formation effectively over short timescales. For studies examining tissue remodeling beyond one week, systemic inflammation resolution, or vascular regeneration, full-length TB-4 becomes necessary. The fragment lacks the N-terminal domain responsible for those broader effects.

The Blunt Truth About TB-4 Nomenclature

Here's what most suppliers won't clarify upfront: the TB-4 versus TB4 question is a red herring. They're identical. The actual problem is that 70–80% of products labeled 'TB-4' or 'TB4' in the research peptide market are TB-500. The cheaper synthetic fragment. Sold under full-length nomenclature without explicit disclosure. This isn't technically mislabeling because TB-500 is derived from TB-4, but it creates reproducibility issues when researchers assume they're replicating studies that used authentic 43-amino-acid Thymosin Beta-4.

The evidence is in the molecular weight data: full-length TB-4 cannot have a molecular weight below 4900 Da, yet certificates of analysis for products labeled 'TB-4' routinely show masses between 850–900 Da. The signature of TB-500. Buyers who don't cross-check specifications against published sequence data end up running experiments with the wrong peptide entirely. At Real Peptides, we label full-length Thymosin Beta-4 explicitly and provide third-party mass spec verification because nomenclature ambiguity undermines research integrity.

Verifying What You Actually Received: Molecular Weight and HPLC Standards

The definitive test for whether your 'TB-4' or 'TB4' product is full-length Thymosin Beta-4 versus the TB-500 fragment is molecular weight confirmation via mass spectrometry. Full-length TB-4 has a calculated molecular weight of 4963.4 Da based on its 43-amino-acid sequence; TB-500 (the 7-amino-acid fragment) weighs approximately 858 Da. Any certificate of analysis showing a mass below 1000 Da confirms you received the fragment, regardless of what the product label claims. HPLC purity above 98% matters, but it doesn't distinguish between full-length and fragment. Both can achieve high purity.

Secondary verification involves reconstitution behavior. Full-length TB-4 requires slightly acidic conditions (pH 5.5–6.5) for optimal solubility and forms a clear solution at concentrations up to 5 mg/mL; TB-500 dissolves readily in neutral pH bacteriostatic water and remains stable at higher concentrations (up to 10 mg/mL). If your peptide crashes out of solution at neutral pH or requires extended vortexing to dissolve, you likely have full-length TB-4. If it dissolves instantly in plain water, suspect TB-500.

Our team cross-references every batch against the published Thymosin Beta-4 sequence (UniProt ID P62328) and provides mass spec data in every shipment. Researchers working with our full peptide collection receive sequence-verified products with transparent molecular weight reporting. Eliminating the guesswork that plagues TB-4 nomenclature across the industry.

The naming confusion around TB-4 versus TB4 dissolves entirely once you verify the amino acid sequence and molecular weight. Both terms refer to the same regenerative peptide. The distinction that matters is confirming you received full-length Thymosin Beta-4 instead of the TB-500 fragment marketed under ambiguous labels. At Real Peptides, sequence transparency and third-party verification ensure research teams know exactly what compound they're working with, regardless of how it's abbreviated.